A therosclerosis is a chronic inflammatory syndrome affecting large and medium sized arteries, the prevalence of which has increased steadily as the population ages. Coronary artery disease is the underlying condition in most acute coronary events and the leading cause of death in developed countries. 1, 2 Previous studies have shown that excessive mitochondrial oxidative stress within the vasculature contributes to the initiation and progression of endothelial dysfunction and atherogenesis. 3, 4 Genetic ablation of manganese superoxide dismutase, or uncoupling protein-2, accelerates atherogenesis in mouse models of atherosclerosis via an increase in mitochondrial oxidative stress. 5, 6 Conversely, overexpression of thioredoxin-2 decreases the atherosclerotic lesion size by enhancing nitric oxide production and lowering reactive oxygen species (ROS). 7 Furthermore, it has recently been shown that increased mitochondrial oxidative stress in lesional macrophages promotes atherogenesis through nuclear factor-κB-mediated monocyte migration into the plaque. 8 It is unknown whether mitochondrial oxidative stress in other lesional cell types contributes to atherogenesis. January 19, 2018 In addition to cells of the innate immune system, the adaptive immune response also partake in orchestrating the progression of atherosclerosis. CD4 + T-cells are one of the most abundant adaptive immune cells in human atherosclerotic plaques 9, 10 ; and they are proatherogenic by promoting inflammation, lesion growth, and plaque instability. 11 Furthermore, depletion of CD4 + T-cells in Ldlr −/− and ApoE −/− murine models of atherosclerosis leads to atheroprotection with a substantial reduction in plaque formation and progression. 12, 13 Because of growing evidence supporting the role of inflammation in atherosclerosis pathophysiology, ongoing clinical trials evaluate the impact of targeting proinflammatory cytokines (eg, interleukin-1β [CANTOS trial (The Canakinumab AntiInflammatory Thrombosis Outcomes Study)], interleukin-6 [ASSAIL-MI (Assessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction)], and tumor necrosis factor-α [CIRT trial (Cardiovascular Inflammation Reduction)]).
14 Although, these studies will inform on the effects of targeting key single effectors of the atherosclerosis inflammatory process, complex pro-and antiatherogenic immune networks operate during disease progression. Consequently, there is a need for broader, multitarget approaches to modulate the immune-mediated events involved in atherosclerosis.
Mesenchymal stromal cells (MSCs) are multipotent cells with unique immunomodulatory properties 15 that justify their use in clinical trials as cellular therapy for prevalent chronic inflammatory conditions (eg, coronary artery disease). [16] [17] [18] A major challenge in this field has been the unpredictable and partially conflicting results from some of those trials. 19 Among the factors contributing to such inconsistent outcomes are issues related to donor heterogeneity, ex vivo MSCs expansion, and cryopreservation. 20 We and others have shown that MSCs from individuals with chronic inflammatory conditions (eg, type 2 diabetes mellitus, atherosclerosis) have reduced immunopotency because of a proinflammatory shift in their secretome. 21, 22 The aim of this study is to assess whether increased mitochondrial oxidative stress in atherosclerotic-MSCs reduces their immunopotency and alters their secretome, thereby promoting atherogenesis.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Subjects
This study was approved by the McGill University-Ethics Board, and participants provided written informed consent. Subcutaneous adipose tissue was obtained from 42 healthy adults undergoing orthopedic surgery (nonatherosclerotic) and 38 adults undergoing programmed coronary artery bypass surgery (atherosclerotic). The demographic information of the study participants is summarized in the Table.
Isolation and Characterization of MSCs
MSCs were isolated from adipose tissue as previously described. 21 Briefly, after enzymatic digestion of adipose tissue (1-8 g), cells were plated in 75-cm 2 tissue culture flasks (1 g of tissue/flask). Two days after isolation, nonadherent cells were washed off, and complete medium ([CM], DMEM supplemented with 10% MSC-qualified fetal bovine serum and 1% penicillin/streptomycin) was added. At 80% confluency, MSCs were trypsinized and subcultured at a density of 5000 cells/cm 2 . Immunophenotypic characterization of MSCs was performed according to criteria established by the International Society for Cellular Therapy by multiparametric flow cytometry (BD LSRII; Becton Dickinson Co, Mountain View, CA). Passage 2 MSCs were stained with fluorochrome-conjugated monoclonal antibodies: fluorescein isothiocyanate-conjugated anti-CD90 and anti-CD45; phycoerythrin-conjugated anti-CD73; allophycocyanin-conjugated anti-CD34, anti-CD19, and anti-HLA-DR; peridinin chlorophyll-conjugated anti-CD105, anti-CD44, and anti-CD14. Data were analyzed with FlowJo software v9.7.2. In all samples, CD73, CD105, CD44 and CD90 surface markers were present in >95% of the events while CD45, CD34, CD19, CD14, and HLA-DR were detected in <5% (Online Figure IA) . What New Information Does This Article Contribute?
Nonstandard Abbreviations and Acronyms
• The signature of human atherosclerotic-MSCs is characterized by mitochondrial dysfunction, oxidative stress, glycolytic metabolic shift, changes in the secretome composition, and increased apoptotic susceptibility.
• Reducing the mitochondrial oxidative stress of atherosclerotic-MSCs shifts their secretome rescuing their potency to suppress T-cell proliferation in vitro.
Using human samples, we show that mitochondrial dysfunction in atherosclerotic-MSCs results in reactive oxygen species overproduction and oxidative stress. This in turn promotes a metabolic phenotypic switch characterized by enhanced glycolysis with reduced ATP production post-priming and an altered secretome with lower immunomodulating ability. Our findings are relevant to the pathogenesis of atherosclerosis because of the potential contribution of dysfunctional MSCs to plaque development and progression. In addition, we outline a mechanism and provide data that support that its modulation results in the improvement of the MSCs in vitro function. This has implications for the optimization of atherosclerotic-MSCs as autologous therapeutic products.
At passage 3, MSCs were plated in 24-well plates at a density of 5000 cells/cm 2 (Online Figure IB) . Cells were incubated in CM for 3 days which was then replaced with 1 of the 3 differentiation media and cultured for 3 weeks as per the manufacture's protocol (StemPro Adipo-, Osteo-, Chondro-genesis Differentiation Kit). MSCs were then fixed with 4% formaldehyde and stained with Alizarin Red S, Oil red O, or Safranin O to assess osteogenic, adipogenic, and chondrogenic differentiation, respectively (Online Figure IC) .
PBMCs Isolation, Carboxyfluorescein Succinimidyl Ester Fluorescent Dye Labeling, and PBMC Activation
Peripheral blood mononuclear cells (PBMCs) were separated using lymphocyte separation medium (Corning) and density-gradient centrifugation. Then, they were cultured in 10% fetal bovine serum RPMI medium (Wisent Biotechnologies) overnight for monocyte depletion. Monocyte-depleted PBMCs were stained with carboxyfluorescein succinimidyl ester (Sigma), and were activated with anti-CD3/CD28 beads (Dynabeads, Life Technologies).
Immunopotency Assay
The capacity of MSCs to suppress proliferating CD4 + T-cells was assessed in a 4-day allogeneic coculture system (ie, MSCs from different donors exposed to the same unrelated primary CD4 + T-cells). MSCs were plated at 25×10 3 cells/well in flat-bottom 96-well plates (Corning) and cultured overnight. Activated monocyte-depleted carboxyfluorescein succinimidyl ester-stained PBMCs (2 ×10 
MSC Priming by PBMCs
MSCs were plated at 75×10 3 cells/well in 24-well plates (Sarstedt) and cultured overnight. Activated monocyte-depleted PBMCs (6×10 5 cells) were then cultured in 0.4-µm polyethylene terephthalate transwell inserts (Millipore) added to the MSC plate (MSCs:PBMCs ratio 1:8). At day 4, the inserts were removed, the MSCs trypsinized, and assigned to the corresponding experiments.
ROS and Mitochondrial Mass Measurement
ROS was determined by the oxidant-sensing probe 2',7'-dichlorodihydrofluorescein diacetate (10 μmol/L; Sigma, Schnelldorf, Germany) 
Mitochondrial Membrane Potential
MSCs mitochondrial membrane potential was measured as previously described. 24 Briefly, MSCs were cultured overnight on poly-llysine-coated glass cover slips. The following day, the medium was changed, supplemented with MitoTracker Red, and MSCs were incubated for 30 minutes at 37°C. MSCs were fixed with 3.7% formaldehyde/PBS, permeabilized with 0.1% Triton X-100, and blocked with 0.05% Tween 20, 5% fetal bovine serum, and 1 mmol/L NaN 3 . Next, MSCs were incubated with primary antibodies against Tom70 overnight. The following day, AlexaFluor488-conjugated secondary antibodies were added and MSCs were stained with DAPI (4',6-diamidino-2-phenylindole). Images were acquired with a Zeiss LSM510 confocal microscope. The Multi Wavelength Cell Scoring Module of MetaXpress software was used for analysis.
Electron Microscopy
MSCs were prepared for electron microscopy as previously described. 23 MSCs were plated in Nunc Lab-Tek Chamber Slides (8 well slides) coated with Permanox at a seeding density of 1×10 4 cells per well. The following day, cells were fixed in 0.1 mol/L phosphate buffer with 2.5% glutaraldehyde and stored at 4°C overnight. Cells were rinsed in 0.1 mol/L phosphate buffer, incubated in fixation buffer supplemented with 1% osmium tetroxide for 1 hour, dehydrated through a graded ethanol series, and embedded in epoxy resin. Ultra-thin sections from the selected areas were contrasted with uranyl acetate and lead citrate and viewed using an FEI Tecnai 12 transmission electron microscope at 120 kV with an XR-80C AMT, 8 megapixel charge-coupled device camera. Micrographs of randomly selected mitochondria were obtained at a final magnification of ×1300. Each mitochondrion was identified manually; the length of mitochondria was measured with an optical pen using ImageJ software.
Metabolic Assays
Respirometry (oxygen consumption rate [OCR] ) and the extracellular acidification rate (ECAR) of MSCs were measured with an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) as described previously. 25, 26 Briefly, MSCs were plated at 1 ×10 4 cells/well in 200 μL nonbuffered DMEM containing 25 mmol/L glucose and 2 mmol/L glutamine. Cells were incubated in a CO 2 -free incubator at 37°C for 1 hour to allow for temperature and pH equilibration before loading into the XF96 apparatus. XF assays consisted of a sequential mix (2 minutes), pause (2 minutes), and measurement (4 minutes) cycles, allowing for determination of OCR/ECAR every 7 minutes. All measurements were normalized to cell number determined with the crystal violet assay.
ATP Concentration
The ATPlite luminescence assay system (PerkinElmer) was used to determine ATP levels. Resting or primed (after coculturing with PBMCs) MSCs were plated in 96-well plates at a density of 10 000 cells per well. After 24 hours, the ATP assay was conducted according to the manufacturer's specifications.
Enzyme-Linked Immunosorbent Assays
MSCs were plated in 96-well plates at a density of 1×10 4 cells/well in 200 µL CM and cultured overnight. After a 24-hour treatment with either N-acetyl-l-cysteine (2 mmol/L, Sigma) or oligomycin (1 μmol/L), the MSCs were washed extensively with PBS. CM was added for 24 hours, and the supernatants were collected and frozen at −80°C. Quantification of interleukin-6, interleukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 was done by enzyme-linked immunosorbent assays (BD Biosciences).
Determination of Histone H2AX Phosphorylation
MSCs were fixed in cytofix solution and permeabilized in 0.5% Triton X-100 (Sigma). Next, cells were incubated in blocking solution and then with a mouse anti-γH2AX (pS139) Alexa Fluor 488 antibody overnight at 4°C and analyzed by flow cytometry. Background was determined using unstained MSCs. Data were analyzed with FlowJo software.
Western Blotting
MSCs were cultured either in resting conditions with CM or primed with interferon-γ (10 ng/mL; R&D systems) and tumor necrosis factor-α (15 ng/mL; R&D systems) for 72 hours. Total protein extracts (10-20 µg) were separated on 10% acrylamidesodium dodecyl sulfate gels and transferred to polyvinylidene fluoride membranes (Millipore). Specific proteins were detected with antimitofusin-2 (MFN-2), antimitochondrial optic atrophy (OPA) 1, antidynamin-related protein-1 (DRP-1), anti-β-tubulin, anti-hypoxia-inducible factor 1-α (HIF1-α), complex I subunit NDUFB8, complex II subunit 30 kDa, complex III subunit core 2, or complex IV subunit II antibodies. β-actin, GAPDH, or α-tubulin were used as loading controls. Anti-mouse or anti-rabbit secondary antibodies were used, and signals were detected using a chemiluminescence system (ECL Plus, Amersham). Image lab software (BioRad) was used for analysis. Specific characteristics of all antibodies are provided in Online Table II .
Statistical Analysis
All analyses were performed with GraphPad Prism software (GraphPad, San Diego), and graphs are presented as box plots. Wilcoxon signed-rank test was used to assess differences following N-acetyll-cysteine, MitoTempo, MitoCP, and Trolox treatments. MannWhitney U test was used to compare nonatherosclerotic-MSCs and atherosclerotic-MSCs. Mean±SD from all comparisons are reported. All hypotheses tests were 2-sided; a P<0.05 was considered statistically significant and is indicated by an asterisk in the figures.
Results

Increased Intracellular ROS Reduce the Immunopotency of MSCs
At physiological concentrations, ROS act as signaling molecules and play an important role in the regulation of various cellular functions, including cell growth, proliferation, apoptosis, and inflammatory responses. 27 However, excessive ROS levels cause oxidative stress, which is implicated in the pathogenesis of various cardiovascular diseases, including atherosclerosis. 28, 29 To determine whether oxidative stress alters MSC immunopotency, we first treated MSCs with H 2 O 2 to increase intracellular ROS levels (Online Figure IIA) . The immunopotency of H 2 O 2 -treated MSCs was assessed in CD4 + T-cell suppression assays. H 2 O 2 treatment increased MSCs intracellular ROS levels (Online Figure IIB) reducing their efficiency to suppress CD4 + T-cell proliferation ( Figure 1A and 1B). This was not associated with changes in T-cell viability ( Figure 1C ).
MSCs From Atherosclerosis Subjects Have Increased Levels of Mitochondrial ROS
Although our group previously reported that atherosclerosis impairs the immunomodulatory function of MSCs, 21 the mechanisms underlying this defect remain elusive. Therefore, we assessed whether MSCs from patients with atherosclerosis (atherosclerotic-MSCs) recapitulate the oxidative stressinduced reduction in MSC immunopotency. Specifically, we compared the redox state of atherosclerotic-MSCs to that in MSCs from individuals without atherosclerosis (nonatherosclerotic-MSCs). Our results indicate that atheroscleroticMSCs have higher intracellular ROS levels (Figure 2A) . Because mitochondria are the major source of ROS, we next assessed mitochondrial oxidative stress by quantifying mitochondrial ROS levels. Indeed, atheroscleroticMSCs have increased mitochondrial oxidative stress than nonatherosclerotic-MSCs ( Figure 2B ). Moreover, atherosclerotic-MSCs are less potent suppressors of CD4 + T-cell proliferation ( Figure 2C ), and the increase in mitochondriaspecific ROS correlates with the reduced immunopotency of MSCs ( Figure 2E ). CD4 + T-cell viability was similar in nonatherosclerotic-MSCs and atherosclerotic-MSCs cocultures ( Figure 2D ). A perturbation in the balance between oxidants and antioxidants in favor of oxidants, potentially promoting cellular damage, is termed oxidative stress. Therefore, we further investigated whether the increased intracellular ROS levels in atherosclerotic-MSCs resulted from a reduction in the antioxidant defense. Nonatherosclerotic-MSCs and atherosclerotic-MSCs have equal abundance of 2 major antioxidant enzymes: catalase and superoxide dismutase. However, we cannot exclude differences in the enzymatic activity of these scavenger systems (Online Figure III) .
Mitochondrial Morphology Is Altered in Atherosclerotic-MSCs
Morphological and structural alterations of mitochondria can lead to mitochondrial dysfunction and excessive intracellular ROS levels. 30 Because atherosclerotic-MSCs display elevated mitochondrial oxidative stress, we next assessed the content (ie, mitochondrial mass), structure, and morphology of their mitochondria. Our results revealed that MSCs from adults with atherosclerosis have increased mitochondrial mass ( Figure 3A ) and elongated mitochondria ( Figure 3B ), 2 features that may reflect an increase in fusion activity. Mitochondrial fusion maximizes oxidative capacity in response to stress by mixing the contents of partially damaged mitochondria by means of complementation. 31 Ultimately, this protective mechanism ensures the maintenance of a functional mitochondrial population. To test whether in atherosclerotic-MSCs the structural mitochondrial changes were associated with defects in fusion or fission, we assessed the levels of 2 members of the dynamin GTPase superfamily that regulate mitochondrial fusion/ fission dynamics (ie, OPA-1 and DRP-1). Our data revealed that atherosclerotic-MSCs have increased total OPA-1 levels and reduced phosphorylated DRP-1-like protein (Ser637), thus providing a potential mechanism for the differences in the atherosclerotic-MSCs mitochondrial morphology (Online Figure IV) .
Mitochondrial morphology is inherently related to function. This is supported by the dynamic reconfigurations of mitochondria that occur in some normal cells and the morphological changes that are associated with various human diseases (eg, diabetes mellitus, neurodegeneration, aging, and cancer).
32,33 Consequently, we investigated whether the altered morphology of atherosclerotic-MSCs was accompanied by changes in mitochondrial membrane potential. Compared with nonatherosclerotic-MSCs, atherosclerotic-MSCs display a reduced mitochondrial membrane potential ( Figure 3C ). In summary, atherosclerotic-MSCs display profound changes in mitochondrial morphology and function relative to nonatherosclerotic-MSCs.
Glycolytic Metabolic Shift of Atherosclerotic-MSCs
Next, we assessed the impact of the increased mitochondrial oxidative stress on the bioenergetic function of atherosclerotic-MSCs by metabolic profiling. Under resting and primed (ie, after MSC activation by PBMCs) conditions, we measured the metabolic activity of nonatherosclerotic-MSCs and atherosclerotic-MSCs by simultaneously monitoring mitochondrial respiration and glycolysis. The primary metabolic function of mitochondria is oxidative phosphorylation (OXPHOS), an energy-generating process that couples the oxidation of respiratory substrates with ATP production. Resting and primed atherosclerotic-MSCs have reduced mitochondrial respiration (OCR: key metric of OXPHOS) and sensitivity to electron transport chain inhibitors than nonatherosclerotic-MSCs ( Figure 4A-4C) . Furthermore, on priming, atherosclerotic-MSCs have similar mitochondrial oxygen consumption but an increased rate of ECAR (rate of conversion of pyruvate to lactic acid, measure of glycolytic activity) compared with nonatheroscleroticMSCs. Interestingly, intracellular ATP levels are not different in resting and primed atherosclerotic-MSCs ( Figure 4D ) while primed nonatherosclerotic-MSCs increase their ATP levels through both OXPHOS and glycolysis ( Figure 4B-4D) . These results suggest that mitochondrial dysfunction in atherosclerotic-MSCs leads to a metabolic switch from OXPHOS to glycolytic energy production.
To assess whether the enhanced glycolytic flux of atherosclerotic-MSCs was associated with a low efficiency and impairment of OXPHOS, we investigated the abundance of OXPHOS protein complexes under resting and primed conditions. The OXPHOS system consists of 5 multimeric protein complexes (I, II, III, IV, and V). Atherosclerotic-MSCs have decreased levels of complex I subunit NDUFB8, complex II subunit (SDHB), complex III subunit core 2, and complex IV subunit COX II (Online Figure V) . These results suggest a potential link between the enhanced glycolysis of atherosclerotic-MSCs and their low mitochondrial respiratory chain activity.
In aged tissues, the accumulation of HIF-1α under normoxic conditions causes a metabolic shift toward glycolysis. 34 Because atherosclerosis is an age-related syndrome, we addressed this in atherosclerotic-MSCs. Despite being cultured under normoxic conditions, atherosclerotic-MSCs have increased HIF-1α protein levels (Online Figure VI) . This could be an additional explanation for the atheroscleroticMSCs metabolic shift (Online Figure IV) .
Spare respiratory capacity (SRC) is the difference between the maximum mitochondrial OCR and the basal mitochondrial OCR. Cells can use SRC to adapt to increased energy demands. The mitochondrial SRC is critical for cellular survival and function [35] [36] [37] [38] [39] ; and higher SRC has been associated with lower ROS generation. 39 Compared with nonatherosclerotic-MSCs, atherosclerotic-MSCs have a lower SRC both under resting and primed conditions ( Figure 4E ). Collectively, our data suggest that atherosclerotic-MSCs not only shift their metabolism toward glycolysis and produce less ATP, but they are also more susceptible to stress and possibly to cell death.
Atherosclerotic-MSCs Have High Levels of HIF-1α and an Altered Secretome
ROS may act as secondary signaling messengers and activate nuclear factor-κB. In turn, nuclear factor-κB enhances the transcription and accumulation of HIF-1α, which then drives the expression of proinflammatory cytokine/chemokine genes. 40 Given the higher abundance of HIF-1α in atherosclerotic-MSCs (Online Figure VI) , we evaluated key cytokines/chemokines in the MSC secretome. Atherosclerotic-MSCs secrete higher levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 than nonatherosclerotic-MSCs in both resting ( Figure 5A-5C ) and primed conditions (Online Figure VII) .
Moreover, oligomycin-induced mitochondrial dysfunction of nonatherosclerotic-MSCs leads to an increase in ROS levels and to a shift in the cytokine/chemokine secretome similar to atherosclerotic-MSCs ( Figure 5D-5F ). Of relevance, oligomycin treatment had no impact on the atherosclerotic-MSC secretome (Online Figure VIII) .
Increased Apoptosis in Atherosclerotic-MSCs
Excessive oxidative stress is cytotoxic because of increased oxidative damage to DNA, proteins, and lipids. 41 Because atherosclerotic-MSCs have higher intracellular ROS levels than nonatherosclerotic-MSCs, we assessed the impact of increased oxidative stress on MSC survival ( Figure 6A) . After priming MSCs, we evaluated mitochondrial membrane potential, DNA damage, autophagic vesicles, and apoptosis. Atherosclerotic-MSCs have lower membrane potential ( Figure 6B ), higher DNA damage ( Figure 6C ), increased number of autophagic vesicles ( Figure 6D and 6E) , and are more prone to apoptosis ( Figure 6F and 6G) .
ROS Reduction Shifts the Atherosclerotic-MSC Secretome and Rescues Their Immunopotency
The MSC secretome plays a key role mediating MSC immunopotency. Modulation of the MSC secretome through pharmacological preconditioning or genetic manipulation before transplantation improves the outcome of MSC-based therapy. [42] [43] [44] [45] We showed that atherosclerotic-MSCs have reduced immunopotency because of a shift in their secretome; and that neutralizing inflammatory-secreted factors enhance MSCs immunomodulatory function. 22 Therefore, we assessed the effects of reducing ROS on the MSC secretome profile. We treated both nonatherosclerotic-MSCs and atherosclerotic-MSCs with the ROS scavenger N-acetyl-l-cysteine and measured key cytokines and chemokines of the MSC secretome. ROS reduction in atherosclerotic-MSCs but not in nonatherosclerotic-MSCs (Online Figure IX) diminishes the levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 ( Figure 7A -7C) in the secretome and enhances atherosclerotic-MSCs survival and immunopotency ( Figure 7D-7G) . Furthermore, the mitochondria-targeted ROS scavengers Trolox, MitoCP, and MitoTempo similarly improve the atherosclerotic-MSCs immunomodulatory capacity ( Figure 7G ).
Discussion
Clinical trials demonstrated the feasibility, safety, and potential therapeutic benefits of autologous adipose-derived MSCs transplantation in various inflammatory conditions, including cardiovascular diseases. The main barrier limiting the translation of these results to clinical practice is intertrial inconsistency. 46, 47 A major contributor to these discrepancies is the variability in the MSCs' immunopotency because of donor-related differences. 48 Previously, our group showed that atherosclerosis impairs MSCs' immunomodulatory function, and this could impact their therapeutic efficiency. 21 Defining the mechanisms underlying the reduced immunopotency of atherosclerotic-MSCs is relevant for MSCs optimization to ultimately enhance their therapeutic efficiency. In the present study, we demonstrate that mitochondria in atherosclerotic-MSCs are dysfunctional leading to an overproduction of ROS. In turn, oxidative stress negatively affects the MSCs immunomodulatory function and promotes a phenotypic switch characterized by enhanced glycolytic metabolism and an altered secretome. Furthermore, we provide evidence that the modulation of ROS levels in atherosclerotic-MSCs enhances their immune-modulatory function.
Excessive ROS levels reduce the osteogenic differentiation and proliferation of MSCs.
49 Here, we demonstrate that H 2 O 2 also reduces the ability of MSCs to suppress T-cell proliferation, a surrogate marker of the overall immunosuppressive capacity of MSCs. 50 Further we show that atherosclerotic-MSCs have higher levels of total intracellular ROS (a negative predictor of the MSCs expansion potential 51 ) and, in particular, elevated mitochondrial ROS levels that correlate with their reduced in vitro immunopotency. Considering that MSCs may play a role in inhibiting inflammation and stabilizing vulnerable atherosclerotic plaques, 52 and the implications of mitochondria to atherosclerosis development, 53 our findings provide the rationale for testing whether restoring mitochondrial dysfunction in atherosclerotic-MSCs could impact atherosclerosis progression reducing the risk of acute events.
The abundance of HIF-1α in atherosclerotic-MSCs is a relevant finding linking their high ROS levels and their metabolic shift. ROS activate the HIF-1α promoter via a functional nuclear factor-κB site, 40 and the HIF1α protein is stabilized by high mitochondrial ROS concentrations. 54 HIF1α regulates the production of numerous glycolytic enzymes 55 and can underlie the glycolytic metabolic shift seen in atheroscleroticMSCs. In certain cancer cells, HIF1α mediates a metabolic reprogramming for which those cells predominantly produce energy by a high rate of aerobic glycolysis followed by lactic acid fermentation in the cytosol (Warburg effect). 56, 57 The generation and modulation of ROS is one of the benefits of the Warburg effect to cancer cells. 58 Similarly, this metabolic reprogramming may also serve as a protective antioxidant mechanism in atherosclerotic-MSCs. Indeed, these cells are exposed to a pro-oxidative (inflammatory) milieu in vivo, and they display elevated basal (resting) ROS levels. Consequently, atherosclerotic-MSCs may shift their metabolism toward glycolysis to avoid excessive and cytotoxic levels of ROS accumulation, thus ensuring their survival.
Increased mitochondrial ROS and downstream HIF1α expression in atherosclerotic-MSCs may also account for the altered secretome of these cells. Indeed, elevated mitochondrial ROS are implicated in the de novo synthesis of NLPR3 (NLR family pyrin domain containing 3) inflammasome protein components. 59 Furthermore, mitochondrial ROS also promote sustained activation of proinflammatory mitogen-activated protein kinases signaling through inhibition of mitogen-activated protein kinases phosphatases. 60 Finally, ROS-induced HIF1α directly regulates inflammatory gene expression and processes in various myeloid and cancer cells. [61] [62] [63] The phenotypic shift of immunomodulatory nonatherosclerotic-MSCs toward proinflammatory atherosclerotic-MSCs resembles the changes seen during macrophage polarization. 64 Specifically, polarization toward the proinflammatory M1 phenotype is also characterized by a shift from OXPHOS toward glycolytic metabolism via HIF1α-dependent mechanisms. 65 The survival rate of transplanted MSCs is a determining factor in the success of cellular therapies. 66 Considering the harsh microenvironment of the ischemic myocardium similar to that of other inflammatory conditions for which MSCs-based therapies are applied, the quality of MSCs pre-transplantation is crucial to ensure their viability and post-transplantation effects. Here, we show that PBMCs' primed atherosclerotic-MSCs, which partially mimics their transplanted microenvironment, are more prone to apoptosis than nonatherosclerotic-MSCs. These data suggest that in atherosclerotic-MSCs, the elevated basal ROS levels, when combined with ROS generated upon PBMC priming, become cytotoxic.
Globally, our observations could be explained by a concentration-centered model of ROS as proposed by Finkel. 67 In this model, low levels of mitochondrial ROS are associated with hypoxic responses mediated (at least in part) by HIF1α involving metabolic adaptations. Moderate levels of mitochondrial ROS are linked to the regulation of inflammatory responses; while high levels are involved in activating apoptosis/autophagy pathways, capable of inducing cell death. Supporting this model, our data show that most of the resting (nonprimed) atherosclerotic-MSCs have moderate levels of ROS. However, PBMC priming of atherosclerotic-MSCs increases their intracellular ROS levels triggering MSCs apoptosis.
Our data point to mitochondria as a suitable pharmacological target to improve the therapeutic potential of MSCs from outcomes (ie, ROS levels, MSC secretome, and apoptosis rates). The lack of differences in these readouts between both groups suggests that atherosclerosis is the main culprit of the reported differences between atherosclerotic-MSCs and nonatherosclerotic-MSCs (Online Table I ; Online Figure X) . Furthermore, previously we showed that the negative effect of atherosclerosis on MSC immunosuppressive ability is more pronounced than that of age. 21 In addition, a recent comparative analysis of a large number of human adipose-derived MSCs showed that the in vitro and in vivo properties were similar and maintained during aging. 68 Although we can not rule out the confounder effect of medications used by the atherosclerotic-MSCs donors, our previous data indicate that neither statins, angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, nor β-blockers predicted differences in the MSCs immunomodulatory function. 21 All together, these data suggest the role of disease as the main culprit of the mitochondrial dysfunction in adult atherosclerotic-MSCs. In vitro pre-treatment of atherosclerotic-MSCs with either a free radical scavenger or with mitochondria-targeted redox-sensitive agents reduced their proinflammatory secretome and increased their survival upon priming. This is relevant because cotreatment with MSCs and N-acetyl-l-cysteine, in an acute myocardial infarction model, improved MSCs engraftment and survival, thus enhancing the overall therapeutic benefit. 69 Both in vitro and in vivo studies documented the protective effects of mitochondria-targeted antioxidants for various conditions. 70, 71 It remains to be tested whether ex vivo treatment of atherosclerotic-MSCs with such compounds could enhance their function.
In conclusion, our work shows that MSCs from subjects with atherosclerosis have higher levels of intracellular ROS because of impaired mitochondrial function. Excessive ROS levels compromise the MSC immunopotency and increase their susceptibility to cell death. Overall, these data suggest that the therapeutic effectiveness of atherosclerotic-MSCs could be impaired compared with those of nonatherosclerotic subjects. This study uncovered cellular mechanisms implicated in the potency of MSC-based therapies that likely contribute to the inter-and intra-trial variability of therapeutic outcomes. Finally, our results suggest strategies to enhance the therapeutic efficacy of autologous atherosclerotic-MSCs. 
